Analysis of severe cutaneous adverse reactions (SCARs) in Taiwan drug-injury relief system: 18-year results

Stern, 2012, Exanthematous drug eruptions, N Engl J Med, 366, 2492, 10.1056/NEJMcp1104080 Chung, 2016, Severe cutaneous adverse drug reactions, J Dermatol, 43, 758, 10.1111/1346-8138.13430 Cho, 2017, Treatments for severe cutaneous adverse reactions, J Immunol Res, 1503709 Yang, 2016, Long-term sequelae of Stevens-Johnson syndrome/toxic epidermal necrolysis, Acta Derm Venereol, 96, 525, 10.2340/00015555-2295 Chen, 2010, Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases, Arch Dermatol, 146, 1373, 10.1001/archdermatol.2010.198 Lipowicz, 2013, Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis, Br J Dermatol, 168, 726, 10.1111/bjd.12133 Duong, 2017, Severe cutaneous adverse reactions to drugs, Lancet, 390, 1996, 10.1016/S0140-6736(16)30378-6 Cacoub, 2011, The DRESS syndrome: a literature review, Am J Med, 124, 588, 10.1016/j.amjmed.2011.01.017 Chen, 2019, A realistic review of the drug-injury relief system in Taiwan: challenges, lessons, and achievements, Clin Pharmacol Ther, 106, 847, 10.1002/cpt.1474 Thong, 2011, Epidemiology and risk factors for drug allergy, Br J Clin Pharmacol, 71, 684, 10.1111/j.1365-2125.2010.03774.x Loo, 2018, A 10-years retrospective study on severe cutaneous adverse reactions (SCARs) in a tertiary hospital in penang, Malaysia, Med J Malaysia, 73, 73 Adler, 2017, Recent advances in the understanding of severe cutaneous adverse reactions, Br J Dermatol, 177, 1234, 10.1111/bjd.15423 Kardaun, 2013, Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study, Br J Dermatol, 169, 1071, 10.1111/bjd.12501 Davidovici, 2008, Israeli RegiSCAR Network. profile of acute generalized exanthematous pustulosis in Israel during 2002-2005: results of the RegiSCAR Study, Isr Med Assoc J, 10, 410 Cho, 2014, Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features, J Am Acad Dermatol, 70, 539, 10.1016/j.jaad.2013.11.015 Chung, 2004, Medical genetics: a marker for Stevens-Johnson syndrome, Nature, 428, 486, 10.1038/428486a Hung, 2006, Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions, Pharmacogenetics Genom, 16, 297, 10.1097/01.fpc.0000199500.46842.4a